-
公开(公告)号：US07230085B2
公开(公告)日：2007-06-12
申请号：US10305268
申请日：2002-11-27
IPC分类号： C12P21/08 , C07K16/44 , G01N33/534 , A61K51/10
CPC分类号： C07K16/2803 , A61K47/6849 , A61K2039/505 , C07K16/44
摘要： The present invention relates to an antibody or antibody fragment that binds to 1,4,7,10-tetrazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA),which is bound to an alkyl-amino group through one of its pendant carb.oxyl groups.
摘要翻译： 本发明涉及与1,4,7,10-四氮环十二烷-N，N'，N“，N'-四乙酸（DOTA）结合的抗体或抗体片段，其结合于烷基 - 氨基通过其一个侧链碳氧基。
-
公开(公告)号：US5965131A
公开(公告)日：1999-10-12
申请号：US731107
申请日：1996-10-09
IPC分类号： A61K38/22 , A61K39/395 , A61K41/00 , A61K45/08 , A61K47/48 , A61K49/00 , A61K51/00 , A61K51/10 , G01N33/531 , G01N33/534 , G01N33/574 , G01N33/68 , A01N37/18 , G01N33/53
CPC分类号： B82Y5/00 , A61K41/0095 , A61K47/48353 , A61K47/4873 , A61K47/48746 , A61K47/48753 , A61K49/0017 , A61K51/1078 , A61K51/1093 , G01N33/531 , G01N33/534 , G01N33/574 , G01N33/686 , A61K2121/00 , A61K2123/00 , Y10S424/90
摘要： An improvement in in vivo pretargeting methods for delivering diagnostic or therapeutic agents to a target site in a mammal uses a clearing agent that binds to the target-binding site of the targeting species, whereby non-bound primary targeting species is cleared from circulation but the clearing agent does not remove the bound primary targeting species. Anti-idiotype antibodies and antibody fragments are preferred clearing agents. Fast clearance is achieved by glycosylating the clearing agent with sugar residues that bind to the hepatic asialoglycoprotein receptor.
-
公开(公告)号：US5958408A
公开(公告)日：1999-09-28
申请号：US972037
申请日：1997-11-17
IPC分类号： A61K38/22 , A61K39/395 , A61K41/00 , A61K45/08 , A61K47/48 , A61K49/00 , A61K51/00 , A61K51/10 , G01N33/531 , G01N33/534 , G01N33/574 , G01N33/68 , C07K16/00 , C12N15/11 , C07M21/00
CPC分类号： B82Y5/00 , A61K41/0095 , A61K47/48353 , A61K47/4873 , A61K47/48746 , A61K47/48753 , A61K49/0017 , A61K51/1078 , A61K51/1093 , G01N33/531 , G01N33/534 , G01N33/574 , G01N33/686 , A61K2121/00 , A61K2123/00 , Y10S424/90
摘要： An improvement in in vivo pretargeting methods for delivering diagnostic or therapeutic agents to a target site in a mammal uses a clearing agent that binds to the target-binding site of the targeting species, whereby non-bound primary targeting species is cleared from circulation but the clearing agent does not remove the bound primary targeting species. Anti-idiotype antibodies and antibody fragments are preferred clearing agents. Fast clearance is achieved by glycosylating the clearing agent with sugar residues that bind to the hepatic asialoglycoprotein receptor.
摘要翻译： 用于将诊断或治疗剂递送到哺乳动物的靶位点的体内预靶向方法的改进使用结合靶向物种的靶结合位点的清除剂，由此未结合的初级靶向物质从循环中清除，但是 清除代理不会删除绑定的主要目标物种。 抗独特型抗体和抗体片段是优选的清除剂。 通过用结合肝脏脱唾液酸糖蛋白受体的糖残基糖基化清除剂来实现快速清除。
-
4.发明授权Use of multispecific, non-covalent complexes for targeted delivery of therapeutics 有权使用多特异性非共价复合物进行靶向递送治疗公开(公告)号：US07833528B2
公开(公告)日：2010-11-16
申请号：US11553814
申请日：2006-10-27
IPC分类号： A61K39/395 , C12P21/04 , C12P21/08 , C07K16/00
CPC分类号： C07K16/44 , A61K47/665 , A61K47/67 , B82Y5/00 , C07K16/3007 , C07K2317/31 , C07K2317/55
摘要： Embodiments of the invention relate to a method for treating target cells, tissues or pathogens in a subject, comprising administering a non-covalently bound complex which comprises a multispecific targeting protein and a hapten-enzyme covalent conjugate, followed by administration of a prodrug that is converted to an active drug by the enzyme. Other embodiments of the invention further relate to kits comprising the non-covalently bound complex or the components to prepare the complex.
摘要翻译： 本发明的实施方案涉及用于治疗受试者中靶细胞，组织或病原体的方法，包括施用包含多特异性靶向蛋白质和半抗原酶共价缀合物的非共价结合复合物，然后施用前药，其为 通过酶转化为活性药物。 本发明的其它实施方案还涉及包含非共价结合复合物或制备复合物的组分的试剂盒。
-
公开(公告)号：US07052872B1
公开(公告)日：2006-05-30
申请号：US09382186
申请日：1999-08-23
IPC分类号： A61K39/395 , C07K16/00 , C12P21/04
CPC分类号： A61K51/109 , A61K47/6853 , A61K47/6893 , A61K47/6897 , A61K47/6899 , B82Y5/00 , C07K16/3007 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
摘要翻译： 本发明涉及具有特异性结合目标组织的至少一个臂和特异性结合可靶向缀合物的至少一个其他臂的双特异性抗体或抗体片段。 可靶向缀合物包含载体部分，其包含或携带至少一个可被所述双特异性抗体或抗体片段的至少一个臂识别的表位。 可靶向缀合物还包含一种或多种治疗剂或诊断剂或酶。 本发明提供用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。
-
公开(公告)号：US20100136626A1
公开(公告)日：2010-06-03
申请号：US12582009
申请日：2009-10-20
CPC分类号： C07K16/468 , A61K47/6863 , A61K47/6899 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
-
7.发明授权Production and use of novel peptide-based agents for use with bi-specific antibodies 有权用于双特异性抗体的新型基于肽的试剂的生产和使用公开(公告)号：US07563439B2
公开(公告)日：2009-07-21
申请号：US11923279
申请日：2007-10-24
IPC分类号： A61K39/395 , C07K16/30 , C07K16/44
CPC分类号： C07K16/468 , A61K47/6863 , A61K47/6899 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. In one embodiment, the invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.
摘要翻译： 本发明涉及一种双特异性抗体或抗体片段，其具有至少一个对靶组织有反应性的臂，以及至少一个对接头部分具有反应性的其它臂。 接头部分包括已经制备抗体的半抗原。 在优选的实施方案中，半抗原是组胺 - 琥珀酰甘氨酸（HSG）。 在更优选的实施方案中，所述至少一个臂包含HSG结合679抗体的CDR序列。 抗原性接头与一种或多种治疗剂或诊断剂或酶缀合。 在一个实施方案中，本发明提供了用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。
-
8.发明申请Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies 有权用于双特异性抗体的新型基于肽的试剂的生产和使用公开(公告)号：US20090246131A1
公开(公告)日：2009-10-01
申请号：US12481233
申请日：2009-06-09
CPC分类号： C07K16/468 , A61K47/6863 , A61K47/6899 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
摘要翻译： 本发明涉及一种双特异性抗体或抗体片段，该双特异性抗体或抗体片段具有至少一个对目标组织有反应性的臂和至少一种其它可靶向缀合物反应的其他臂。 可靶向缀合物包含已制备抗体的半抗原。 在优选的实施方案中，半抗原是组胺 - 琥珀酰甘氨酸（HSG）。 在更优选的实施方案中，所述至少一个臂包含HSG结合679抗体的CDR序列。 可靶向缀合物连接至一种或多种治疗和/或诊断剂。 本发明提供了用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法和包含它们的试剂盒。
-
公开(公告)号：US07074405B1
公开(公告)日：2006-07-11
申请号：US09337756
申请日：1999-06-22
IPC分类号： A61K39/395
CPC分类号： C07K16/468 , A61K47/67 , A61K47/6853 , A61K47/6863 , A61K47/6879 , A61K47/6893 , A61K47/6897 , A61K51/088 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K16/18 , C07K16/3007 , C07K16/4266 , C07K16/44 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
摘要翻译： 本发明涉及具有特异性结合目标组织的至少一个臂和特异性结合可靶向缀合物的至少一个其他臂的双特异性抗体或抗体片段。 可靶向缀合物包含载体部分，其包含或携带至少一个可被所述双特异性抗体或抗体片段的至少一个臂识别的表位。 可靶向缀合物还包含一种或多种治疗剂或诊断剂或酶。 本发明提供用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。
-
10.发明授权Production and use of novel peptide-based agents for use with bi-specific antibodies 失效用于双特异性抗体的新型基于肽的试剂的生产和使用公开(公告)号：US06962702B2
公开(公告)日：2005-11-08
申请号：US09823746
申请日：2001-04-03
IPC分类号： G01R33/28 , A61B5/055 , A61K39/395 , A61K49/00 , A61K51/00 , A61K51/08 , A61K51/10 , C07K5/107 , C07K5/11 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/44 , C07K16/46 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12P21/08 , C12Q1/68 , G01N33/50 , G01N33/574 , G01N33/577
CPC分类号： C07K16/468 , A61K47/6863 , A61K47/6899 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.
摘要翻译： 本发明涉及一种双特异性抗体或抗体片段，其具有至少一个对靶组织有反应性的臂，以及至少一个对接头部分具有反应性的其它臂。 接头部分包括已经制备抗体的半抗原。 抗原性接头与一种或多种治疗剂或诊断剂或酶缀合。 本发明提供了用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。
-
-
-
-
-
-
-
-
-
搜索结果
64 条记录 (耗时 0.038 秒)
